Last reviewed · How we verify

NCT03146130: NoISE-PD

Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders

Status unknown Phase 3 Last updated 6 August 2018
What this trial tests

Phase 3 trial testing Variation of behaviors of Parkinson's disease in Impulse Control Disorder in 70 participants. Status unknown.

Timeline
5 July 2018
Primary endpoint
20 December 2019
20 December 2019

Quick facts

Lead sponsorCentre Hospitalier Universitaire, Amiens
PhasePhase 3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment70
Start date5 July 2018
Primary completion20 December 2019
Estimated completion20 December 2019
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire, Amiens

Who can join

18 and older, any sex, with Impulse Control Disorder or Parkinson. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Impulse control disorders encountered in Parkinson's disease (PD) are induced by dopaminergic medications and their frequency is estimated to be nearly 20%, mainly under dopaminergic agonists (AD).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Overview on the Effects of <i>N</i>-Acetylcysteine in Neurodegenerative Diseases.
    Tardiolo G, Bramanti P, Mazzon E. · · 2018 · cited 197× · PMID 30551603 · DOI 10.3390/molecules23123305

Verify or expand the search:

Other recruiting trials for Impulse Control Disorder

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire, Amiens trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03146130.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing